We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




Interventional Oncology Tumor Analysis and Therapy Solution Unveiled

By HospiMedica International staff writers
Posted on 21 Sep 2016
A new interventional oncology solution for minimally invasive liver cancer treatment has been unveiled by a large medical imaging equipment manufacturer.

This is the first solution that is optimized for use with radiopaque beads that minimize damage to healthy tissue, and organs, during tumor treatment.

Royal Philips (Amsterdam, the Netherlands) introduced the OncoSuite solution that provides complete coverage of the liver enabling clinicians to visualize peripheral hepatic tumors, and provide analysis, and minimally invasive, targeted tumor lesion treatment. More...
The solution gives clinicians an improved view of treatment targets during a procedure.

The Philips OncoSuite enhances tumor embolization and ablation procedures, and works together with Philips interventional X-Ray systems. The OncoSuite enables targeted treatment of an entire tumor, and feeder vessels, while minimizing damage to surrounding organs, and healthy tissues.

Minimally invasive, image-guided interventional oncology procedures provide an alternative for patients who cannot be treated using conventional surgery, chemotherapy or radiation therapy.

Dr. Jeff Geschwind, chairman and chief of the Department of Radiology and Biomedical Imaging, Yale School of Medicine, said, “While OncoSuite can be used for a number of different cancers including bone, kidney and lung, the solution and its specific tools have been optimized for the treatment of patients with liver cancer. Given the steady increase in the prevalence of non-alcoholic fatty liver disease and liver cancer, the development and availability of new technology is much needed to provide interventional oncologists with a breakthrough that allows best possible treatment for these patients.”

Related Links:
Royal Philips


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Infant Incubator
OKM 801
X-Ray System
Leonardo DR mini III
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.